Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The adverse effect of FOPNL genomic variant is reversed by bortezomib-based treatment protocols in multiple myeloma.

Leukemia & lymphoma - 1 Mar 2018

Kiss Katalin Piroska, Varga Gergely, Mikala Gabor, Balassa Katalin, Bors Andras, Kovy Petra, Meggyesi Nora, Kozma Andras, Csacsovszki Otto, Remenyi Peter, Valyi-Nagy Istvan, Tordai Attila, Masszi Tamas, Andrikovics Hajnalka

Abstract excerpt

Fibroblast growth factor receptor 1 oncogene partner N-terminal like gene (FOPNL) rs72773978 polymorphism was identified as an adverse prognostic factor in multiple myeloma (MM). We aimed to investigate the associations of rs72773978 with clinical characteristics and treatment outcome in 373 Hungarian MM patients. In our cohort, FOPNL polymorphism showed differential prognostic effect that depended on the...

Read the complete abstract on PubMed

Topics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Bortezomib
Share to Follow-Up Studies
Share to Genomics
Share to Multiple Myeloma
Share to Prognosis
Share to Proteins
Share to Survival Rate

Source

Identifiers

PMID: 28691553
DOI: 10.1080/10428194.2017.1346250

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The adverse effect of FOPNL genomic variant is reversed by bortezomib-based treatment protocols in multiple myeloma.PMID 28691553Read ↗

Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients.Semantic proximity Read ↗

Proteasome Subunit Beta Type 1 P11A Polymorphism Is a New Prognostic Marker in Multiple Myeloma.Semantic proximity Read ↗

Germline genetic variants in Turkish familial multiple myeloma/monoclonal gammopathy of undetermined significance cases.Semantic proximity Read ↗

Cereblon and IRF4 Variants Affect Risk and Response to Treatment in Multiple Myeloma.Semantic proximity Read ↗

Impact of Genetic Polymorphisms in NF-ĸB2 and TRAF3 Genes on Response to Bortezomib-Based Therapy in Multiple Myeloma Patients.Semantic proximity Read ↗

Impact of Genetic Polymorphisms on Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma: A Systematic Review and Bioinformatics Analysis.Semantic proximity Read ↗

Association between BCL2 interacting protein 3 like (BNIP3L) genetic polymorphisms and the risk of multiple myeloma in China.Semantic proximity Read ↗

Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma.Semantic proximity Read ↗

Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision MedicineSemantic proximity Read ↗

Polymorphisms within genes encoding Ikaros family proteins IKZF1 and IKZF3 in multiple myeloma patients treated with thalidomide.Semantic proximity Read ↗

NFKB1 -94ins/delATTG polymorphism is a novel prognostic marker in first line-treated multiple myeloma.Semantic proximity Read ↗

Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.